Company / R&D per Share
Avalo Therapeutics, Inc. R&D per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.78
FY2025
5-year range
$0.80 / $350.79
FY2021-FY2025
Trend
-84.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $350.79 to $4.78 over the past 2 years.
Based on SEC 10-K filings.
4.78 in FY2025 with a 5-year CAGR of +45.8%.
Declined from $350.79 to $4.78 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +12.8%
- 5-Year CAGR
- +45.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share decreased 84.3% year-over-year.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.78 | -84.3% |
| FY2024 | $30.48 | -91.3% |
| FY2023 | $350.79 | +10431.7% |
| FY2022 | $3.33 | +317.5% |
| FY2021 | $0.80 | +10.0% |
| FY2020 | $0.73 | +151.6% |
| FY2019 | $0.29 | +55.8% |
| FY2018 | $0.19 | -60.1% |
| FY2017 | $0.46 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026